When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. J&J, Bristol Myers lose challenges to US drug price ...

   www.aol.com/news/j-j-bristol-myers-lose...

   Eliquis brought Bristol Myers about $8.52 billion in U.S. sales last year, while J&J recorded $2.36 billion in Xarelto sales. Eliquis is shared with Pfizer and Xarelto with Bayer, which were not ...

3. Rivaroxaban - Wikipedia

   en.wikipedia.org/wiki/Rivaroxaban

   Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8 ]

4. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]

5. Xarelto - Wikipedia

   en.wikipedia.org/?title=Xarelto&redirect=no

   This page was last edited on 20 December 2023, at 19:47 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.

6. Johnson & Johnson - Wikipedia

   en.wikipedia.org/wiki/Johnson_&_Johnson

   Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange.

7. AOL Mail is free and helps keep you safe.

   mail.aol.com/?icid=aol.com-nav

   Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!

8. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4]

9. Black health advocacy group calls for more Illinois tax ...

   www.aol.com/news/black-health-advocacy-group...

   (The Center Square) - An Illinois-based Black health advocacy group is demanding more tax dollars for Black HIV care. Officials from the group Black Leadership Advocacy Coalition for Healthcare ...